JNJ forecasts 2025 profit dilution from Intra-Cellular deal, sets closing date

Sundry Photography/iStock Editorial via Getty Images Johnson & Johnson ( NYSE: JNJ ) said that its acquisition of Intra-Cellular Therapies is expected to be completed on or around April 2, 2025, pending approvals. The company corrected an earlier mistaken report stating that the transaction had already been closed on Tuesday..